NEW YORK, NY and SOUTH SAN FRANCISCO, CA, January 7, 2022 – Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Cytokinetics has secured long-term capital from Royalty Pharma to support the potential commercialization of omecamtiv 

NEW YORK, NY, January 6, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2022 of $0.19 per Class A share, reflecting a 12% increase in the company’s quarterly dividend over the previous quarter’s dividend.

NEW YORK, NY, January 5, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET.   The webcast will be accessible from Royalty Pharma’s “Events” page at

NEW YORK, NY, November 29, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 4 th Annual HealthCONx Virtual Conference on December 2, 2021 at 9:40 a.m. ET.   The webcast will be accessible from Royalty Pharma’s

NEW YORK, NY and RESEARCH TRIANGLE PARK, NC, November 22, 2021 – Royalty Pharma plc (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and OMERS Capital Markets (OMERS) today announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closing.

NEW YORK, NY, November 10, 2021 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts⁽¹⁾ (a non-GAAP financial measure).

NEW YORK, NY, October 18, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter of 2021 financial results on Wednesday, November 10, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

NEW YORK, NY, October 15, 2021 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2021 of $0.17 per Class A ordinary share. The dividend will be paid on December 15, 2021, to shareholders of record at the close of business

NEW YORK, NY, September 3, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 16th Annual BioPharma Virtual Conference on Thursday, September 9 at 10:40 a.m.

NEW YORK, NY, August 11, 2021 -  Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts⁽¹⁾ (a non-GAAP financial measure).